clinical trial · NCT07504458
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia (APL)Acute Promyelocytic LeukaemiaAcute Promyelocytic Leukemia With PML-RARAAcute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARAAcute Promyelocytic LeukemiaQTX-2101 + ATRAIV arsenic trioxide (ATO) + ATRA
brief summary
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
started
Jun 8, 2026
primary completion
Mar 1, 2027
completion
Dec 1, 2030
last updated
Jun 16, 2026
official title
A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol